Previous 10 | Next 10 |
2024-06-11 09:11:12 ET More on Incyte Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript Incyte Corporation 2024 Q1 - Results - Earnings Call Presentation Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) Incyte a new hold at Deutsche Bank as ...
Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the preliminary results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at...
2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 14,090 shares of the Company’s common stock and stock option awards to purchase an aggregate of 9,238 shares of the Company’s common stock to 17 new employees. The a...
2024-05-31 21:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to patients Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery...
2024-05-23 12:43:05 ET More on Incyte Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) Incyte jumps 6%, intends to buy back $2B stock Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M Incyte Corporation (INCY) Q1 202...
2024-05-23 08:00:10 ET James Shin from Deutsche Bank issued a price target of $55.00 for INCY on 2024-05-23 06:54:00. The adjusted price target was set to $55.00. At the time of the announcement, INCY was trading at $58.2. The overall price target consensus is at $85.64 ...
Incyte (Nasdaq:INCY) today announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmington. This acquisition marks Incyte’s fourth expansion in Delaware since establishing operations in ...
Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA20...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...